Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Jan-Feb;32(1):122-7.
doi: 10.1111/j.1528-1157.1991.tb05622.x.

Immunologic aspects of carbamazepine treatment in epileptic patients

Affiliations

Immunologic aspects of carbamazepine treatment in epileptic patients

R Pacifici et al. Epilepsia. 1991 Jan-Feb.

Abstract

Immune abnormalities have been found in epileptic patients receiving antiepileptic drugs (AEDs). Phenytoin (PHT) produces a decrease in serum IgA and IgM levels and a decrease in blastic transformation of circulating lymphocytes stimulated with phytohemoagglutinin (PHA). The effects of carbamazepine (CBZ) on the immune response are still conflicting. To elucidate the effects of CBZ on some immunologic parameters, serum concentrations of IgA, IgG, IgM, the phagocytosis and killing properties of polymorphonuclear leukocytes (PMNs), the cytotoxic activity of natural killer cells and the response of lymphocytes to mitogenic agents were studied. Forty healthy individuals and 39 epileptic patients treated with carbamazepine (CBZ) monotherapy (age range 18-40 years) entered the study. Student's t test was used to evaluate the data. CBZ had no effect on the serum immunoglobulin concentrations or on lymphocytic reactivity to phytohemoagglutinin (PHA) mitogen. CBZ produced a significant enhancement of phagocytosis and killing properties of PMNs and an increase in natural killer (NK) cell activity. Therefore, a negative effect of CBZ therapy on the immune system was not observed in this study.

PubMed Disclaimer